Skip to main content

Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meeting


WALTHAM, Mass., October 31, 2023 – Immunitas Therapeutics (“Immunitas”), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced it will present the first proof-of-concept data on its second program, a myeloid and B cell modulating anti CLEC2DToll-like receptor 9 (TLR9) agonist conjugate, at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), held November 1-5.  

Presentation Details for SITC 2023
Title: Anti CLEC2D-TLR9 agonist conjugate binds to and internalizes CLEC2D on myeloid cells, plasmacytoid DCs and B cells leading to robust TLR pathway activation and inflammatory cytokine production
Abstract Number: 1131
Date/Time: Friday, November 3, 2023, 9:00am – 7:00pm PDT  

Press Release